Evidence map›Paper›PMID 32491262›Full record

ArticleCancer medicine2020

Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea.

Jihyun Kwon, So Young Kim, Kyoung Eun Yeob, Hye Sook Han, Ki Hyeong Lee, Dong Wook Shin, Yeon-Yong Kim, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Clinical and Genomic Profiles of Korean Patients withAnnals of laboratory medicine · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jihyun KwonDivision of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
So Young KimDepartment of Public Health and Preventive Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Kyoung Eun YeobCollege of Medicine/Graduate School of Health Science Business Convergence, Chungbuk National University, Cheongju, Korea.
Hye Sook HanDivision of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Ki Hyeong LeeDivision of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Dong Wook ShinSupportive Care Center/Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Yeon-Yong KimBig Data Steering Department, National Health Insurance Service, Wonju, Korea.
Jong Heon ParkBig Data Steering Department, National Health Insurance Service, Wonju, Korea.
Jong Hyock ParkCollege of Medicine/Graduate School of Health Science Business Convergence, Chungbuk National University, Cheongju, Korea.ORCID 0000-0003-3247-0827
Ichiro KawachiT. H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Harvard University · USChungbuk National University · KRNational Health Insurance Service · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the patterns of diagnosis, treatment, and prognoses of acute myeloid leukemia (AML) patients with and without disabilities. The data were collected from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claim database. We built a cohort of 2 776 450 people with disabilities and a nondisabled cohort of 8 329 350 people who were selected at a ratio of 1:3 by matching age and sex. From this population, adult patients who were diagnosed with AML were analyzed. The number of patients with AML were 26.74 per 100 000 in people without disabilities and 20.39 per 100 000 in those with disabilities (P < .0001). The proportion of AML patients receiving chemotherapy and those of patients receiving transplants were significantly lower in the disabled population than that of nondisabled populations (71.2% vs 77.1%, P = .0031, and 17.5% vs 26.9%, P = .002). This trend was more pronounced in subgroups of communication disability and major internal organ disorder. The median survival was 10.8 months for patients with disabilities, which was significantly shorter than 17.1 months for those without a disability (P = .002). Individuals with disabilities have a low diagnosis rate of AML and undergo less active treatment, which results in inferior prognosis.

Indexed as

AgedCohort StudiesFemaleHumansLeukemia, Myeloid, AcuteMaleRepublic of KoreaSurvival Analysisacute myeloid leukemiacohortdisabilitysurvivaltreatment

Identifiers

PMID32491262
PMCPMC7402831
OpenAlexW3028679534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.